Antimuscarinic and beta-3 adrenergic agonist combination

This page covers all Antimuscarinic and beta-3 adrenergic agonist combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Muscarinic M3 receptor and beta-3 adrenergic receptor.

Targets

Muscarinic M3 receptor and beta-3 adrenergic receptor

Marketed (1)

• tolterodine , mirabegron · Far Eastern Memorial Hospital · Urology
  Tolterodine and mirabegron work together to reduce overactive bladder symptoms through complementary pathways: tolterodine blocks muscarinic receptors to decrease bladder contractions, while mirabegron activates beta-3 adrenergic receptors to relax the detrusor muscle.

Patent intelligence

• antimuscarinic and beta 3 adrenergic agonist combination patent landscape — aggregated cliff calendar, attackable patents, originator estates